UK govt requests review of AstraZeneca-Oxford vaccine

AstraZeneca CEO, Pascal Soriot, on Thursday said that the company was likely to run additional trials of its vaccine candidate to validate its efficacy. MHRA’s CEO June Raine said that the regulatory body will “rigorously” assess the latest data and evidence to determine the vaccine’s safety, quality and effectiveness, before giving its approval for its roll-out. EPA-EFE/DAN HIMBRECHTS AUSTRALIA AND NEW ZEALAND OUT

A general view of an analytical chemist at AstraZeneca?s headquarters in Sydney, Australia, 19 August 2020. AstraZeneca and its partner, the University of Oxford, have been facing criticism about their Covid-19 vaccine trial results after acknowledging a manufacturing error. Surprisingly, the group of volunteers that got a lower dose seemed to be much better protected than the volunteers who got two full doses of the vaccine. style=”font-size:40px; line-height: 1.3em; font-weight: 800; padding:7px;”>UK govt requests review of AstraZeneca-Oxford vaccine

By Elena Pavlovska
Journalist

epa08612064 A general view of an analytical chemist at AstraZeneca?s headquarters in Sydney, Australia, 19 August 2020. Australian Prime Minister Scott Morrison announced Australians will be among the first in the world to receive a COVID-19 vaccine, if it proves successful, through an agreement between the government and UK-based drug company AstraZeneca. Our role is to work to the highest standards and safety is our watch word”, Raine said, adding that the MHRA will also seek advice from the Commission on Human Medicines. “The safety of the public will always come first. Australian Prime Minister Scott Morrison announced Australians will be among the first in the world to receive a COVID-19 vaccine, if it proves successful, through an agreement between the government and UK-based drug company AstraZeneca. EPA-EFE/DAN HIMBRECHTS

Facebook

Twitter

Linkedin

WhatsApp

Viber

Email

Print

The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) on Friday confirmed it has received a request from the government’s Department of Health and Social Care to assess AstraZeneca’s COVID-19 vaccine.